| A next generation connectivity map: L1000 platform and the first 1,000,000 profiles A Subramanian, R Narayan, SM Corsello, DD Peck, TE Natoli, X Lu, ... Cell 171 (6), 1437-1452. e17, 2017 | 2674 | 2017 |
| Copper induces cell death by targeting lipoylated TCA cycle proteins P Tsvetkov, S Coy, B Petrova, M Dreishpoon, A Verma, M Abdusamad, ... Science 375 (6586), 1254-1261, 2022 | 2149 | 2022 |
| The Drug Repurposing Hub: a next-generation drug library and information resource SM Corsello, JA Bittker, Z Liu, J Gould, P McCarren, JE Hirschman, ... Nature medicine 23 (4), 405-408, 2017 | 845 | 2017 |
| Discovering the anticancer potential of non-oncology drugs by systematic viability profiling SM Corsello, RT Nagari, RD Spangler, J Rossen, M Kocak, JG Bryan, ... Nature cancer 1 (2), 235-248, 2020 | 566 | 2020 |
| The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K M Słabicki, Z Kozicka, G Petzold, YD Li, M Manojkumar, RD Bunker, ... Nature 585 (7824), 293-297, 2020 | 277 | 2020 |
| A functional landscape of resistance to ALK inhibition in lung cancer FH Wilson, CM Johannessen, F Piccioni, P Tamayo, JW Kim, ... Cancer cell 27 (3), 397-408, 2015 | 187 | 2015 |
| Gefitinib induces myeloid differentiation of acute myeloid leukemia K Stegmaier, SM Corsello, KN Ross, JS Wong, DJ DeAngelo, TR Golub Blood 106 (8), 2841-2848, 2005 | 156 | 2005 |
| Systematic functional interrogation of rare cancer variants identifies oncogenic alleles E Kim, N Ilic, Y Shrestha, L Zou, A Kamburov, C Zhu, X Yang, R Lubonja, ... Cancer discovery 6 (7), 714-726, 2016 | 154 | 2016 |
| Intrinsic resistance to immune checkpoint blockade in a mismatch repair–deficient colorectal cancer C Gurjao, D Liu, M Hofree, SH AlDubayan, I Wakiro, MJ Su, K Felt, E Gjini, ... Cancer immunology research 7 (8), 1230-1236, 2019 | 71 | 2019 |
| Identification of AML1-ETO modulators by chemical genomics SM Corsello, G Roti, KN Ross, KT Chow, I Galinsky, DJ DeAngelo, ... Blood, The Journal of the American Society of Hematology 113 (24), 6193-6205, 2009 | 62 | 2009 |
| Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study AA Ghazani, NM Oliver, JP St Pierre, A Garofalo, IR Rainville, E Hiller, ... Genetics in Medicine 19 (7), 787-795, 2017 | 57 | 2017 |
| Non-oncology drugs are a source of previously unappreciated anti-cancer activity SM Corsello, RT Nagari, RD Spangler, J Rossen, M Kocak, JG Bryan, ... BioRxiv, 730119, 2019 | 38 | 2019 |
| RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition L Fang, D Ford-Roshon, M Russo, C O’Brien, X Xiong, C Gurjao, ... Nature communications 13 (1), 3181, 2022 | 31 | 2022 |
| Virtual screening for small-molecule pathway regulators by image-profile matching MH Rohban, AM Fuller, C Tan, JT Goldstein, D Syangtan, A Gutnick, ... Cell systems 13 (9), 724-736. e9, 2022 | 26 | 2022 |
| Structure-based design of Y-shaped covalent TEAD inhibitors W Lu, M Fan, W Ji, J Tse, I You, SB Ficarro, I Tavares, J Che, AY Kim, ... Journal of medicinal chemistry 66 (7), 4617-4632, 2023 | 9 | 2023 |
| Programmatic precision oncology decision support for patients with gastrointestinal cancer RB Keller, T Mazor, L Sholl, AJ Aguirre, H Singh, N Sethi, A Bass, ... JCO Precision Oncology 7, e2200342, 2023 | 7 | 2023 |
| RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer H Singh, P Sahgal, K Kapner, SM Corsello, H Gupta, R Gujrathi, YY Li, ... Clinical Cancer Research 30 (8), 1669-1684, 2024 | 1 | 2024 |
| Proteomics‐Based Discovery of First‐in‐Class Chemical Probes for Programmed Cell Death Protein 2 (PDCD2) W Ji, WS Byun, W Lu, X Zhu, KA Donovan, BG Dwyer, J Che, L Yuan, ... Angewandte Chemie International Edition 62 (43), e202308292, 2023 | 1 | 2023 |
| 3-amino-2-[2-(acylamino) pyridin-4-yl]-1, 5, 6, 7-tetrahydro-4h-pyrrolo [3, 2-c] pyridin-4-one as csnk1 inhibitors V Schulze, A Mengel, J Schroeder, ACFA DE LEMOS, B Wilhelm, ... US Patent App. 17/428,730, 2023 | 1 | 2023 |
| RNF43 G659fs is an oncogenic mutation in colorectal cancer and sensitizes tumor cells to PI3K/mTOR inhibition L Fang, D Ford-Roshon, M Russo, C O'Brien, C Gurjao, M Grandclaudon, ... Cancer Research 81 (13_Supplement), 960-960, 2021 | 1 | 2021 |
